dc.contributor
Institut Català de la Salut
dc.contributor
[Fakih M] City of Hope Comprehensive Cancer Center, Duarte, USA. [Ciardiello F] Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Prager GW] Department of Medicine I, Medical University Vienna, Vienna, Austria. [Élez E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Calleja E] Taiho Oncology, Inc., Princeton, USA. [Caussé-Amellal N] Servier International Research Institute, Suresnes, France
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Elez, Elena
dc.contributor.author
Calleja, Elizabeth
dc.contributor.author
Caussé-Amellal, Nadia
dc.contributor.author
Fakih, Marwan
dc.contributor.author
Ciardiello, Fortunato
dc.contributor.author
Prager, Gerhard
dc.date.accessioned
2025-10-25T05:36:55Z
dc.date.available
2025-10-25T05:36:55Z
dc.date.issued
2025-08-12T06:57:22Z
dc.date.issued
2025-08-12T06:57:22Z
dc.identifier
Fakih M, Ciardiello F, Prager GW, Élez E, Calleja E, Caussé-Amellal N, et al. Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab. ESMO Gastrointest Oncol. 2025 Sep;9:100191.
dc.identifier
http://hdl.handle.net/11351/13523
dc.identifier
10.1016/j.esmogo.2025.100191
dc.identifier.uri
http://hdl.handle.net/11351/13523
dc.description.abstract
Adverse event; Metastatic colorectal cancer; Safety
dc.description.abstract
Esdeveniment advers; Càncer colorectal metastàtic; Seguretat
dc.description.abstract
Evento adverso; Cáncer colorrectal metastásico; Seguridad
dc.description.abstract
For patients with metastatic colorectal cancer (mCRC) that is refractory to standard chemotherapy, a recommended standard-of-care treatment in the third-line setting is trifluridine/tipiracil (FTD/TPI) alone or in combination with bevacizumab; other treatment options include fruquintinib or regorafenib. The safety profiles of FTD/TPI and bevacizumab as individual agents are well characterized. Common adverse events (AEs) associated with FTD/TPI include neutropenia, anemia, nausea, and diarrhea, and AEs frequently observed with bevacizumab include hypertension, proteinuria, hemorrhage, venous thromboembolism, and gastrointestinal perforation. Approval of the combination of FTD/TPI plus bevacizumab for the treatment of patients with refractory mCRC in the United States and Europe was based on results from the phase III SUNLIGHT trial. There is clinical value in developing a specific set of recommendations for the prevention or management of the key AEs associated with the combination regimen to inform clinical care and improve patient benefit. In this review, we summarize the safety profile of combination treatment with FTD/TPI plus bevacizumab in patients with refractory mCRC who were enrolled in the SUNLIGHT trial, with a focus on the key AEs of neutropenia, anemia, nausea or vomiting, diarrhea, fatigue, hypertension, and hemorrhage. In addition, we provide recommendations for the management or prevention of these key AEs in clinical practice, based on published literature and expert opinions on effective strategies.
dc.description.abstract
This work was supported by Taiho Oncology, Inc (no grant number). Medical writing assistance was provided by Farhana Burnett, PhD, CMPP, of Envision Pharma Group, funded by Taiho Oncology, Inc (no grant number).
dc.format
application/pdf
dc.relation
ESMO Gastrointestinal Oncology;9
dc.relation
https://doi.org/10.1016/j.esmogo.2025.100191
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Còlon - Càncer - Tractament
dc.subject
Recte - Càncer - Tractament
dc.subject
Quimioteràpia combinada
dc.subject
Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.title
Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
